Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where G. Brunori is active.

Publication


Featured researches published by G. Brunori.


Nephron Clinical Practice | 2005

A High Calcium-Phosphate Product Is Associated with High C-Reactive Protein Concentrations in Hemodialysis Patients

Ezio Movilli; Annalisa Feliciani; Corrado Camerini; G. Brunori; Roberto Zubani; Francesco Scolari; Giovanni Parrinello; Giovanni Cancarini

Background: An elevated Ca×PO<sub>4</sub> product and C-reactive protein (CRP) have been associated with coronary artery calcification and increased cardiovascular mortality in hemodialysis (HD) patients. However, it has not been defined, so far, whether and how both parameters are related to each other. For this reason we have evaluated in a cross-sectional and in an interventional study the possible correlation between Ca×PO<sub>4</sub> and CRP and the effect of the correction of a high Ca×PO<sub>4</sub> on CRP levels. Methods: 47 uremic patients (age 65 ± 16 years) on regular chronic HD were selected from a total population of 125 prevalent patients treated at our Institution. Patients had no clinical evidence of either acute infectious or inflammatory diseases for at least 4 weeks before the study. They were on regular bicarbonate HD for 6–329 months (median 42). CRP, hemoglobin (Hb), serum albumin (sAlb), protein catabolic rate (PCRn), serum calcium (Ca), serum phosphorus (PO<sub>4</sub>), Ca×PO<sub>4</sub>, intact PTH, Kt/V, presence of ischemic heart disease (IHD) and/or peripheral vascular disease (PVD) were recorded. CRP was Ln-transformed in all statistical analyses because of positive skewness. Results: The main findings were: LnCRP 2.17 ± 0.77 mg/l, Ca 10.1 ± 0.4 mg/dl, PO<sub>4</sub> 5.8 ± 0.6 mg/dl, Ca×PO<sub>4</sub> 59 ± 6 mg<sup>2</sup>/dl<sup>2</sup>, andPTHint 218 ± 195 ng/ml. 18/47 had IHD, 18/47 PVD. A significant hyperbolic correlation between Ca×PO<sub>4</sub> and CRP was observed. A piecewise linear regression model analysis identified a break-point for Ca×PO<sub>4</sub> at 55 mg<sup>2</sup>/dl<sup>2</sup>. Comparison of CRP levels after the division of the patients into two groups according to Ca×PO<sub>4</sub> break-point (group A, Ca×PO<sub>4</sub> ≤55 mg<sup>2</sup>/dl<sup>2</sup>, n = 16 patients; group B, Ca×PO<sub>4</sub> >55 mg<sup>2</sup>/dl<sup>2</sup>, n = 31 patients) showed that CRP levels were significantly lower in patients in group A (LnCRP 1.43 ± 0.22 mg/l) than in group B (LnCRP 2.55 ± 0.67 mg/l, p < 0.0001). Multiple regression analysis bearing LnCRP as dependent variable confirmed Ca×PO<sub>4</sub> as the most significant variable among the other variables examined. In 22 patients with Ca×PO<sub>4</sub> ≧60 mg<sup>2</sup>/dl<sup>2</sup>, we performed intensive lowering of the Ca×PO<sub>4</sub> product in order to reach and maintain a Ca×PO<sub>4</sub> ≤55 mg<sup>2</sup>/dl<sup>2</sup> for 3 months. At the end of observation, a significant reduction in Ca×PO<sub>4</sub> and LnCRP was observed (Ca×PO<sub>4</sub> pre 62.8 ± 1.9 vs. post 46.3 ± 6.2 mg<sup>2</sup>/dl<sup>2</sup>: p < 0.0001; LnCRP pre 2.32 ± 0.36 vs. post 1.83 ± 0.14 mg/l: p < 0.0001). No significant variation in the other biochemical parameters was observed. Conclusions: Our data show that in chronic HD patients in steady clinical conditions with no clinical evidence of either infectious or inflammatory diseases, a high Ca×PO<sub>4</sub> is associated with high CRP concentrations. Intensive lowering of Ca×PO<sub>4</sub> reduces CRP.


Nephrology Dialysis Transplantation | 1995

Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study.

R. Maiorca; G. Brunori; Roberto Zubani; Giovanni Cancarini; Luigi Manili; Corrado Camerini; Ezio Movilli; Alessandra Pola; G. d'Avolio; U. Gelatti


Peritoneal Dialysis International | 1996

CAPD viability: a long-term comparison with hemodialysis

R Maiorca; Giovanni Cancarini; Roberto Zubani; Corrado Camerini; Luigi Manili; G. Brunori; Ezio Movilli


Nephrology Dialysis Transplantation | 1989

Is CAPD Competitive with Haemodialysis for Long-term Treatment of Uraemic Patients?

R. Malorca; Giovanni Cancarini; Corrado Camerini; G. Brunori; Luigi Manili; Ezio Movilli; Paolo Feller; S. Mombelloni


Nephrology Dialysis Transplantation | 1995

Which treatment for which patient in the future? Possible modifications in CAPD

R. Maiorca; Giovanni Cancarini; G. Brunori; Roberto Zubani; Corrado Camerini; Luigi Manili; M. Campanini; S. Mombelloni


Nephrology Dialysis Transplantation | 2004

Inter-dialytic variations in blood volume and total body water in uraemic patients treated by dialysis

Ezio Movilli; Giovanni Cancarini; Silvia Cassamali; Corrado Camerini; G. Brunori; Camilla Maffei; R. Maiorca


Nephrology Dialysis Transplantation | 1995

Influence of protein catabolic rate on nutritional status, morbidity and mortality in elderly uraemic patients on chronic haemodialysis: a prospective 3-year follow-up study

Ezio Movilli; M. Fillippini; G. Brunori; Massimo Sandrini; E. Costantino; L. Cristinelli; R. Maiorca


Nephrology Dialysis Transplantation | 1996

Differing dialysis treatment strategies and outcome

R. Maiorca; Giovanni Cancarini; Roberto Zubani; Ezio Movilli; G. Brunori


Journal of Vascular Access | 2000

Which vascular access for chronic hemodialysis in uremic elderly patients

G. Brunori; F. Verzelletti; Roberto Zubani; Ezio Movilli; Mario Gaggiotti; Giovanni Cancarini; R. Maiorca


Peritoneal Dialysis International | 1997

Long-term outcomes of peritoneal dialysis.

Giovanni Cancarini; G. Brunori; Zani R; Roberto Zubani; Alessandra Pola; Sandrini M; Zein H; R. Maiorca

Collaboration


Dive into the G. Brunori's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge